DJIA 15,973.84 313.66 2.00%
NASDAQ 4,337.51 70.68 1.66%
S&P 500 1,864.78 35.70 1.95%
market minute promo

Medivation, Inc. (NASDAQ: MDVN)



company name or ticker

4 Blockbuster Drugs Whose Sales Could Easily Double

These drugs are already generating -- or on pace to generate -- more than $1 billion in annual sales, yet they're capable of so much more.

Better Buy Now: Medivation Inc vs Jazz Pharmaceuticals

These two mid-cap healthcare companies have been stellar long-term investments, but which company is the better buy today?

3 Cancer Companies to Watch Closely in 2016

These biotech companies should find out if their cancer drugs can pass muster with the FDA next year.

J&J's Earnings May Be Good News for Bristol-Myers Squibb and Medivation

Slowing sales for two top-selling therapies may mean that competitors gained ground last month.

How This Biotech Stock Hopes to Become More Than a One Trick Pony

Medivation acquired a late stage breast cancer drug from BioMarin in August.

Drugs Stocks On The Rise With Help From 3 Stocks

Wild Short Interest Swings For These Three Biotech Stocks

Trade-Ideas: Medivation (MDVN) Is Today's "Dead Cat Bounce" Stock

Sanofi, Eli Lilly Agree to Settle Lantus Patent Litigation

Genomic Health Posts Positive Breast Cancer Trial Results

See More Articles...